APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Vaccine for Human

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oral Vaccine for Human Industry Research Report 2026

29 December 2025131 pages

Choose your research edition.

Industry ResearchOral Vaccine for Human Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Vaccine for Human Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oral Vaccine for Human Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Vaccine for Human Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Vaccine for Human Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Oral Vaccine for Human market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Oral Vaccine for Human is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Oral Vaccine for Human is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Oral Vaccine for Human include Bibcol, Bio-Med, EuBiologics, Halfkin Bio-Pharmaceuticals, Panacea Biotec Ltd, PaxVax, Serum Institute, Vabiotech and Valneva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Oral Vaccine for Human market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oral Vaccine for Human Market by Company

Bibcol

Bio-Med

EuBiologics

Halfkin Bio-Pharmaceuticals

Panacea Biotec Ltd

PaxVax

Serum Institute

Vabiotech

Valneva

Tiantan Biological

GSK

Merck

Sanofi

Shanghai United Cell

Lanzhou Institute

Oral Vaccine for Human Segment by Type

Cholera Vaccine

Oral Polio Vaccine

Rotavirus Vaccine

Other

Oral Vaccine for Human Segment by Application

Public

Private

Oral Vaccine for Human Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Vaccine for Human market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Vaccine for Human and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Vaccine for Human.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Oral Vaccine for Human manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Oral Vaccine for Human by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Oral Vaccine for Human in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oral Vaccine for Human Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Oral Vaccine for Human Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Oral Vaccine for Human Sales Market Share by Manufacturers (2021-2026) Table 8. Global Oral Vaccine for Human Revenue of Manufacturers (2021-2026) Table 9. Global Oral Vaccine for Human Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Oral Vaccine for Human Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Oral Vaccine for Human Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Oral Vaccine for Human, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Oral Vaccine for Human, Product Type & Application Table 14. Global Oral Vaccine for Human Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Oral Vaccine for Human by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Bibcol Company Information Table 19. Bibcol Business Overview Table 20. Bibcol Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Bibcol Oral Vaccine for Human Product Portfolio Table 22. Bibcol Recent Developments Table 23. Bio-Med Company Information Table 24. Bio-Med Business Overview Table 25. Bio-Med Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bio-Med Oral Vaccine for Human Product Portfolio Table 27. Bio-Med Recent Developments Table 28. EuBiologics Company Information Table 29. EuBiologics Business Overview Table 30. EuBiologics Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. EuBiologics Oral Vaccine for Human Product Portfolio Table 32. EuBiologics Recent Developments Table 33. Halfkin Bio-Pharmaceuticals Company Information Table 34. Halfkin Bio-Pharmaceuticals Business Overview Table 35. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio Table 37. Halfkin Bio-Pharmaceuticals Recent Developments Table 38. Panacea Biotec Ltd Company Information Table 39. Panacea Biotec Ltd Business Overview Table 40. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio Table 42. Panacea Biotec Ltd Recent Developments Table 43. PaxVax Company Information Table 44. PaxVax Business Overview Table 45. PaxVax Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. PaxVax Oral Vaccine for Human Product Portfolio Table 47. PaxVax Recent Developments Table 48. Serum Institute Company Information Table 49. Serum Institute Business Overview Table 50. Serum Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Serum Institute Oral Vaccine for Human Product Portfolio Table 52. Serum Institute Recent Developments Table 53. Vabiotech Company Information Table 54. Vabiotech Business Overview Table 55. Vabiotech Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Vabiotech Oral Vaccine for Human Product Portfolio Table 57. Vabiotech Recent Developments Table 58. Valneva Company Information Table 59. Valneva Business Overview Table 60. Valneva Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Valneva Oral Vaccine for Human Product Portfolio Table 62. Valneva Recent Developments Table 63. Tiantan Biological Company Information Table 64. Tiantan Biological Business Overview Table 65. Tiantan Biological Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Tiantan Biological Oral Vaccine for Human Product Portfolio Table 67. Tiantan Biological Recent Developments Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. GSK Oral Vaccine for Human Product Portfolio Table 72. GSK Recent Developments Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Merck Oral Vaccine for Human Product Portfolio Table 77. Merck Recent Developments Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Sanofi Oral Vaccine for Human Product Portfolio Table 82. Sanofi Recent Developments Table 83. Shanghai United Cell Company Information Table 84. Shanghai United Cell Business Overview Table 85. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Shanghai United Cell Oral Vaccine for Human Product Portfolio Table 87. Shanghai United Cell Recent Developments Table 88. Lanzhou Institute Company Information Table 89. Lanzhou Institute Business Overview Table 90. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Lanzhou Institute Oral Vaccine for Human Product Portfolio Table 92. Lanzhou Institute Recent Developments Table 93. Global Oral Vaccine for Human Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Oral Vaccine for Human Sales by Region (2021-2026) & (K Units) Table 95. Global Oral Vaccine for Human Sales Market Share by Region (2021-2026) Table 96. Global Oral Vaccine for Human Sales by Region (2027-2032) & (K Units) Table 97. Global Oral Vaccine for Human Sales Market Share by Region (2027-2032) Table 98. Global Oral Vaccine for Human Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Oral Vaccine for Human Revenue Market Share by Region (2021-2026) Table 100. Global Oral Vaccine for Human Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Oral Vaccine for Human Revenue Market Share by Region (2027-2032) Table 102. North America Oral Vaccine for Human Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 104. North America Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 105. North America Oral Vaccine for Human Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Oral Vaccine for Human Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Oral Vaccine for Human Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 109. Europe Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 110. Europe Oral Vaccine for Human Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Oral Vaccine for Human Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Oral Vaccine for Human Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Oral Vaccine for Human Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Oral Vaccine for Human Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Oral Vaccine for Human Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 119. South America Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 120. South America Oral Vaccine for Human Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Oral Vaccine for Human Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Oral Vaccine for Human Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Oral Vaccine for Human Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Oral Vaccine for Human Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 128. Global Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 129. Global Oral Vaccine for Human Sales Market Share by Type (2021-2026) Table 130. Global Oral Vaccine for Human Sales Market Share by Type (2027-2032) Table 131. Global Oral Vaccine for Human Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Oral Vaccine for Human Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Oral Vaccine for Human Revenue Market Share by Type (2021-2026) Table 134. Global Oral Vaccine for Human Revenue Market Share by Type (2027-2032) Table 135. Global Oral Vaccine for Human Price by Type (2021-2026) & (US$/Unit) Table 136. Global Oral Vaccine for Human Price by Type (2027-2032) & (US$/Unit) Table 137. Global Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 138. Global Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 139. Global Oral Vaccine for Human Sales Market Share by Application (2021-2026) Table 140. Global Oral Vaccine for Human Sales Market Share by Application (2027-2032) Table 141. Global Oral Vaccine for Human Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Oral Vaccine for Human Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Oral Vaccine for Human Revenue Market Share by Application (2021-2026) Table 144. Global Oral Vaccine for Human Revenue Market Share by Application (2027-2032) Table 145. Global Oral Vaccine for Human Price by Application (2021-2026) & (US$/Unit) Table 146. Global Oral Vaccine for Human Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Oral Vaccine for Human Distributors List Table 150. Oral Vaccine for Human Customers List Table 151. Oral Vaccine for Human Industry Trends Table 152. Oral Vaccine for Human Industry Drivers Table 153. Oral Vaccine for Human Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oral Vaccine for Human Product Image Figure 5. Global Oral Vaccine for Human Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Oral Vaccine for Human Market Size (2021-2032) & (US$ Million) Figure 7. Global Oral Vaccine for Human Sales (2021-2032) & (K Units) Figure 8. Global Oral Vaccine for Human Average Price (US$/Unit) & (2021-2032) Figure 9. Cholera Vaccine Product Image Figure 10. Oral Polio Vaccine Product Image Figure 11. Rotavirus Vaccine Product Image Figure 12. Other Product Image Figure 13. Public Product Image Figure 14. Private Product Image Figure 15. Global Oral Vaccine for Human Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Oral Vaccine for Human, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Oral Vaccine for Human Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Oral Vaccine for Human Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Oral Vaccine for Human Sales by Region in 2025 Figure 21. Global Oral Vaccine for Human Revenue by Region in 2025 Figure 22. North America Oral Vaccine for Human Market Size by Country in 2025 Figure 23. North America Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 24. North America Oral Vaccine for Human Revenue Market Share by Country (2021-2032) Figure 25. United States Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Oral Vaccine for Human Market Size by Country in 2025 Figure 28. Europe Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 29. Europe Oral Vaccine for Human Revenue Market Share by Country (2021-2032) Figure 30. Germany Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Netherlands Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Oral Vaccine for Human Market Size by Country in 2025 Figure 36. Asia Pacific Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Oral Vaccine for Human Revenue Market Share by Country (2021-2032) Figure 38. China Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Oral Vaccine for Human Market Size by Country in 2025 Figure 47. South America Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 48. South America Oral Vaccine for Human Revenue Market Share by Country (2021-2032) Figure 49. Mexico Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Middle East and Africa Oral Vaccine for Human Market Size by Country in 2025 Figure 53. Middle East and Africa Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 54. Middle East and Africa Oral Vaccine for Human Revenue Market Share by Country (2021-2032) Figure 55. Turkey Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Saudi Arabia Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. UAE Oral Vaccine for Human Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Global Oral Vaccine for Human Sales Market Share by Type (2021-2032) Figure 59. Global Oral Vaccine for Human Revenue Market Share by Type (2021-2032) Figure 60. Global Oral Vaccine for Human Price (US$/Unit) by Type (2021-2032) Figure 61. Global Oral Vaccine for Human Sales Market Share by Application (2021-2032) Figure 62. Global Oral Vaccine for Human Revenue Market Share by Application (2021-2032) Figure 63. Global Oral Vaccine for Human Price (US$/Unit) by Application (2021-2032) Figure 64. Oral Vaccine for Human Value Chain Figure 65. Oral Vaccine for Human Production Mode & Process Figure 66. Direct Comparison with Distribution Share Figure 67. Distributors Profiles Figure 68. Oral Vaccine for Human Industry Opportunities and Challenges

Scope & coverage.

Types
  • Cholera Vaccine
  • Oral Polio Vaccine
  • Rotavirus Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Bibcol
  • Bio-Med
  • EuBiologics
  • Halfkin Bio-Pharmaceuticals
  • Panacea Biotec Ltd
  • PaxVax
  • Serum Institute
  • Vabiotech
  • Valneva
  • Tiantan Biological
  • GSK
  • Merck
  • Sanofi
  • Shanghai United Cell
  • Lanzhou Institute

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Oral Vaccine for Human Market Size (2021-2032)
  4. 2.2.2 Global Oral Vaccine for Human Sales (2021-2032)
  5. 2.2.3 Global Oral Vaccine for Human Market Average Price (2021-2032)
  6. 2.3 Oral Vaccine for Human by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Cholera Vaccine
  9. 2.3.3 Oral Polio Vaccine
  10. 2.3.4 Rotavirus Vaccine
  11. 2.3.5 Other
  12. 2.4 Oral Vaccine for Human by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Public
  15. 2.4.3 Private
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Oral Vaccine for Human Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Oral Vaccine for Human Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Oral Vaccine for Human Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Oral Vaccine for Human Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Oral Vaccine for Human Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Oral Vaccine for Human, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Oral Vaccine for Human, Product Type & Application
  8. 3.8 Global Manufacturers of Oral Vaccine for Human, Established Date
  9. 3.9 Global Oral Vaccine for Human Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Bibcol
  2. 4.1.1 Bibcol Company Information
  3. 4.1.2 Bibcol Business Overview
  4. 4.1.3 Bibcol Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Bibcol Oral Vaccine for Human Product Portfolio
  6. 4.1.5 Bibcol Recent Developments
  7. 4.2 Bio-Med
  8. 4.2.1 Bio-Med Company Information
  9. 4.2.2 Bio-Med Business Overview
  10. 4.2.3 Bio-Med Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bio-Med Oral Vaccine for Human Product Portfolio
  12. 4.2.5 Bio-Med Recent Developments
  13. 4.3 EuBiologics
  14. 4.3.1 EuBiologics Company Information
  15. 4.3.2 EuBiologics Business Overview
  16. 4.3.3 EuBiologics Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 EuBiologics Oral Vaccine for Human Product Portfolio
  18. 4.3.5 EuBiologics Recent Developments
  19. 4.4 Halfkin Bio-Pharmaceuticals
  20. 4.4.1 Halfkin Bio-Pharmaceuticals Company Information
  21. 4.4.2 Halfkin Bio-Pharmaceuticals Business Overview
  22. 4.4.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio
  24. 4.4.5 Halfkin Bio-Pharmaceuticals Recent Developments
  25. 4.5 Panacea Biotec Ltd
  26. 4.5.1 Panacea Biotec Ltd Company Information
  27. 4.5.2 Panacea Biotec Ltd Business Overview
  28. 4.5.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio
  30. 4.5.5 Panacea Biotec Ltd Recent Developments
  31. 4.6 PaxVax
  32. 4.6.1 PaxVax Company Information
  33. 4.6.2 PaxVax Business Overview
  34. 4.6.3 PaxVax Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 PaxVax Oral Vaccine for Human Product Portfolio
  36. 4.6.5 PaxVax Recent Developments
  37. 4.7 Serum Institute
  38. 4.7.1 Serum Institute Company Information
  39. 4.7.2 Serum Institute Business Overview
  40. 4.7.3 Serum Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Serum Institute Oral Vaccine for Human Product Portfolio
  42. 4.7.5 Serum Institute Recent Developments
  43. 4.8 Vabiotech
  44. 4.8.1 Vabiotech Company Information
  45. 4.8.2 Vabiotech Business Overview
  46. 4.8.3 Vabiotech Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Vabiotech Oral Vaccine for Human Product Portfolio
  48. 4.8.5 Vabiotech Recent Developments
  49. 4.9 Valneva
  50. 4.9.1 Valneva Company Information
  51. 4.9.2 Valneva Business Overview
  52. 4.9.3 Valneva Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Valneva Oral Vaccine for Human Product Portfolio
  54. 4.9.5 Valneva Recent Developments
  55. 4.10 Tiantan Biological
  56. 4.10.1 Tiantan Biological Company Information
  57. 4.10.2 Tiantan Biological Business Overview
  58. 4.10.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Tiantan Biological Oral Vaccine for Human Product Portfolio
  60. 4.10.5 Tiantan Biological Recent Developments
  61. 4.11 GSK
  62. 4.11.1 GSK Company Information
  63. 4.11.2 GSK Business Overview
  64. 4.11.3 GSK Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 GSK Oral Vaccine for Human Product Portfolio
  66. 4.11.5 GSK Recent Developments
  67. 4.12 Merck
  68. 4.12.1 Merck Company Information
  69. 4.12.2 Merck Business Overview
  70. 4.12.3 Merck Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Merck Oral Vaccine for Human Product Portfolio
  72. 4.12.5 Merck Recent Developments
  73. 4.13 Sanofi
  74. 4.13.1 Sanofi Company Information
  75. 4.13.2 Sanofi Business Overview
  76. 4.13.3 Sanofi Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Sanofi Oral Vaccine for Human Product Portfolio
  78. 4.13.5 Sanofi Recent Developments
  79. 4.14 Shanghai United Cell
  80. 4.14.1 Shanghai United Cell Company Information
  81. 4.14.2 Shanghai United Cell Business Overview
  82. 4.14.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Shanghai United Cell Oral Vaccine for Human Product Portfolio
  84. 4.14.5 Shanghai United Cell Recent Developments
  85. 4.15 Lanzhou Institute
  86. 4.15.1 Lanzhou Institute Company Information
  87. 4.15.2 Lanzhou Institute Business Overview
  88. 4.15.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Lanzhou Institute Oral Vaccine for Human Product Portfolio
  90. 4.15.5 Lanzhou Institute Recent Developments
5 Global Oral Vaccine for Human Market Scenario by Region
  1. 5.1 Global Oral Vaccine for Human Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Oral Vaccine for Human Sales by Region: 2021-2032
  3. 5.2.1 Global Oral Vaccine for Human Sales by Region: 2021-2026
  4. 5.2.2 Global Oral Vaccine for Human Sales by Region: 2027-2032
  5. 5.3 Global Oral Vaccine for Human Revenue by Region: 2021-2032
  6. 5.3.1 Global Oral Vaccine for Human Revenue by Region: 2021-2026
  7. 5.3.2 Global Oral Vaccine for Human Revenue by Region: 2027-2032
  8. 5.4 North America Oral Vaccine for Human Market Facts & Figures by Country
  9. 5.4.1 North America Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Oral Vaccine for Human Sales by Country (2021-2032)
  11. 5.4.3 North America Oral Vaccine for Human Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Oral Vaccine for Human Market Facts & Figures by Country
  15. 5.5.1 Europe Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Oral Vaccine for Human Sales by Country (2021-2032)
  17. 5.5.3 Europe Oral Vaccine for Human Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Oral Vaccine for Human Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Oral Vaccine for Human Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Oral Vaccine for Human Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Oral Vaccine for Human Market Facts & Figures by Country
  35. 5.7.1 South America Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Oral Vaccine for Human Sales by Country (2021-2032)
  37. 5.7.3 South America Oral Vaccine for Human Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Oral Vaccine for Human Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Oral Vaccine for Human Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Oral Vaccine for Human Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Oral Vaccine for Human Sales by Type (2021-2032)
  2. 6.1.1 Global Oral Vaccine for Human Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Oral Vaccine for Human Sales Market Share by Type (2021-2032)
  4. 6.2 Global Oral Vaccine for Human Revenue by Type (2021-2032)
  5. 6.2.1 Global Oral Vaccine for Human Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Oral Vaccine for Human Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Oral Vaccine for Human Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Oral Vaccine for Human Sales by Application (2021-2032)
  2. 7.1.1 Global Oral Vaccine for Human Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Oral Vaccine for Human Sales Market Share by Application (2021-2032)
  4. 7.2 Global Oral Vaccine for Human Revenue by Application (2021-2032)
  5. 7.2.1 Global Oral Vaccine for Human Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Oral Vaccine for Human Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Oral Vaccine for Human Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Oral Vaccine for Human Value Chain Analysis
  2. 8.1.1 Oral Vaccine for Human Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Oral Vaccine for Human Production Mode & Process
  5. 8.2 Oral Vaccine for Human Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Oral Vaccine for Human Distributors
  8. 8.2.3 Oral Vaccine for Human Customers
9 Global Oral Vaccine for Human Analyzing Market Dynamics
  1. 9.1 Oral Vaccine for Human Industry Trends
  2. 9.2 Oral Vaccine for Human Industry Drivers
  3. 9.3 Oral Vaccine for Human Industry Opportunities and Challenges
  4. 9.4 Oral Vaccine for Human Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst